<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158792</url>
  </required_header>
  <id_info>
    <org_study_id>LAU.SOP.NC1.25/Jun/2015</org_study_id>
    <nct_id>NCT03158792</nct_id>
  </id_info>
  <brief_title>Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function</brief_title>
  <official_title>Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lebanese American University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lebanese American University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial including non-surgical patients, 70 years of age or older, with
      renal impairment requiring pharmacological venous thromboembolism prevention during
      hospitalization. Patients are randomized to receive either 20 mg or 30mg of enoxaparin. Both
      dosing regimens of enoxaparin have been approved for thromboprophylaxis in impaired kidney
      function in different countries. Therefore, this study aims to evaluate the efficacy and
      safety of enoxaparin 20mg versus 30mg subcutaneously daily by comparing anti-xa levels,
      thrombosis and bleeding events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2015</start_date>
  <completion_date type="Actual">July 13, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak anti-Xa levels</measure>
    <time_frame>Day 3 of thromboprophylaxis</time_frame>
    <description>Peak anti-Xa levels, drawn 4 hours after the enoxaparin dose is given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough anti-xa levels</measure>
    <time_frame>Day 3 of thromboprophylaxis</time_frame>
    <description>Trough anti-Xa levels, drawn right before the third enoxaparin dose is given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding according to the GUSTO bleeding criteria.</measure>
    <time_frame>Bleeding within 30 days will be assessed from randomization till date of bleeding or date of discharge, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objectively confirmed symptomatic or asymptomatic venous thromboembolism (VTE) including both deep vein thrombosis (DVT) and or pulmonary embolism (PE).</measure>
    <time_frame>Venous thromboembolism (VTE) within 30 days will be assessed from randomization till date of VTE or date of discharge, whichever comes first.</time_frame>
    <description>Chart documentation of objectively detected DVT by either bilateral venography or duplex ultrasonography whereas PE detection by contrast enhanced computerized tomography scan (CT Scan) or Magnetic resonance imaging (MRI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Enoxaparin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 30 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 20Mg/0.2mL Prefilled Syringe</intervention_name>
    <description>Enoxaparin 20mg subcutaneously once daily</description>
    <arm_group_label>Enoxaparin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml</intervention_name>
    <description>Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered</description>
    <arm_group_label>Enoxaparin 30 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-surgical patients

          -  70 years of age or older

          -  With renal impairment (creatinine clearance â‰¤35ml/min)

          -  Requiring pharmacological thromboprophylaxis

        Exclusion Criteria:

          -  Indication for a treatment dose of anticoagulant treatment

          -  Knee surgery or hip surgery within 10 to 35 days, respectively

          -  Surgery, trauma, hemodialysis, peritoneal dialysis, or bleeding

          -  History of heparin-induced thrombocytopenia

          -  Known or suspected hypersensitivity to any component of study drug

          -  Patients with an excessive risk of bleeding and not eligible for pharmacological
             thromboprophylaxis based on physician assessment or due to any of the 3 major risk
             factors including active gastroduodenal ulcer, bleeding within the past three months
             prior to hospital admission, or a platelet count of &lt;50,000 platelets/ mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nibal R Chamoun, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lebanese American University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LAU Medical Center-Rizk Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lebanese American University</investigator_affiliation>
    <investigator_full_name>Nibal Chamoun</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Pharmacy Practice and Clinical Coordinator</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Anti-Xa levels</keyword>
  <keyword>Elderly</keyword>
  <keyword>Prevention</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Low molecular weight heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

